Management of common mental disorders in primary care
One major theme of the work within the Centre is the management of the common mental disorders of depression and anxiety in primary care (Leads: Dr David Kessler, Dr Nicola Wiles). There is a particular interest in the clinical and cost-effectiveness of interventions for individuals whose depression has not responded to treatment with antidepressants (MIR and CoBalT) as well as the application of new technologies to increase the efficiency of, and widen access to, cognitive behavioural therapy. Other research is focused on translating findings from basic cognitive science to help us understand the mechanisms underlying psychological interventions in order to improve mental health outcomes in primary care.
Selected current or recent grants
- Wiles N, Kessler D, Welton N, Wevill C, Coyle D, Turner K, Churchill R, Parrott S, Williams C, Lewis G, Nazareth I, Shafran R, Gilbody S, Peters T, Mcleod U, Lanham P. Integrated therapist and online CBT for depression in primary care. NIHR Programme Grant for Applied Research. £2, 233, 801. 2016 - 2022
- Lewis G, Nazareth I, King M, Kessler D, Gilbody S, Freemantle N, Hunter R, Kendrick A, Moore M, Wiles N. Antidepressants to prevent relapse in depression. NIHR Health Technology Assessment Programme. £1,668,028. 2016-2019
- Kessler D, Hollingworth W, Lewis G, Davies S, Wiles NJ, Peters TJ, Chew-Graham C, Gilbody S, Anderson I, Macleod U, Campbell J, Dickens C. A double-blind placebo controlled randomised trial of the addition of the antidepressant mirtazapine for patients with depression in primary care who have not responded to treatment with a selective serotonin reuptake inhibitor (MIR). NIHR Health Technology Assessment Programme. £2,115,330. 2012 – 2017.
- Lewis G, Araya R, Churchill R, Hollingworth W, Kessler D, Peters TJ, Welton N, Wiles NJ, Ades T, Malpass A, Dowrick C, Robinson J, Kendrick T, Gilbody S, Croudace T. What are the indications for prescribing antidepressants that will lead to clinical benefit? (PANDA). NIHR Programme Grant for Applied Research. £1,999,968. 2012 – 2017
- Wiles NJ, Lewis G, Sharp D, Kessler D, Peters T, Hollinghurst S, Turner K, Jerrom B, Campbell J, Kuyken W, Morrison J, Williams C. Cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment resistant depression in primary care: a randomised controlled trial (CoBalT). NIHR Health Technology Assessment Programme. £1,561,156. 2008 – 2014
- French L, Thomas L, Campbell J, Kuyken W, Lewis G, Williams C, Wiles NJ, Turner KM. Individuals’ long term use of cognitive behavioural skills to manage their depression: a qualitative study. Behav Cog Psychother (2017) 45 (1): 46-57
- Mars, B., Heron, J., Gunnell, D., Martin, R., Thomas, K., Kessler, D., Prevalence and patterns of antidepressants switiching amongt Primary Care patients in the UK. J. Psychopharmacol. 31 (5): 553-560
- Percival, J., Donovan, J., Kessler, D., Turner,K. 'She believed in me'. What patients with depression value in their relationshop with practitioners: A secondary analysis of multiple qualitative data sets. Health Expectations 20(1): 85-97
- Tallon D, Wiles N, Campbell J, Chew-Graham C, Dickens C, Macleod U, Peters T, Lewis G, Anderson I, Gilbody S, Hollingworth W, Davies S, Kessler D, “Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial” Trials 2016 17:66
- Wiles N, Thomas L, Turner N, Garfield K, Kounali D, Campbell J, Kessler D, Kuyken W, Lewis G, Morrison J, Williams C, Peters TJ, Hollinghurst S. Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment resistant depression in primary care: follow-up of the CoBalT trial The Lancet Psychiatry (2016) 3(2): 137-144
- Burrage A, Green S, Turner K, Kuyken W, Williams C, Wiles N, Lewis G. Conditional Beliefs of Primary-Care Patients with Treatment-Resistant Depression Behav Cog Psychother (2016) 44(5): 513-526